Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Defining the Phenotype and Assessing Severity in Phosphoglucomutase-1 Deficiency

SY. Wong, LJ. Beamer, T. Gadomski, T. Honzik, M. Mohamed, SB. Wortmann, KS. Brocke Holmefjord, M. Mork, F. Bowling, J. Sykut-Cegielska, D. Koch, A. Ackermann, CA. Stanley, D. Rymen, A. Zeharia, M. Al-Sayed, T. Marquardt, J. Jaeken, D. Lefeber,...

. 2016 ; 175 (-) : 130-136.e8. [pub] 20160517

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023967

Grantová podpora
NV16-31932A MZ0 CEP - Centrální evidence projektů

OBJECTIVE: To define phenotypic groups and identify predictors of disease severity in patients with phosphoglucomutase-1 deficiency (PGM1-CDG). STUDY DESIGN: We evaluated 27 patients with PGM1-CDG who were divided into 3 phenotypic groups, and group assignment was validated by a scoring system, the Tulane PGM1-CDG Rating Scale (TPCRS). This scale evaluates measurable clinical features of PGM1-CDG. We examined the relationship between genotype, enzyme activity, and TPCRS score by using regression analysis. Associations between the most common clinical features and disease severity were evaluated by principal component analysis. RESULTS: We found a statistically significant stratification of the TPCRS scores among the phenotypic groups (P < .001). Regression analysis showed that there is no significant correlation between genotype, enzyme activity, and TPCRS score. Principal component analysis identified 5 variables that contributed to 54% variance in the cohort and are predictive of disease severity: congenital malformation, cardiac involvement, endocrine deficiency, myopathy, and growth. CONCLUSIONS: We established a scoring algorithm to reliably evaluate disease severity in patients with PGM1-CDG on the basis of their clinical history and presentation. We also identified 5 clinical features that are predictors of disease severity; 2 of these features can be evaluated by physical examination, without the need for specific diagnostic testing and thus allow for rapid assessment and initiation of therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023967
003      
CZ-PrNML
005      
20170830104112.0
007      
ta
008      
170720s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jpeds.2016.04.021 $2 doi
035    __
$a (PubMed)27206562
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Wong, Sunnie Yan-Wai $u Hayward Genetics Center, Tulane University School of Medicine, New Orleans, LA. Electronic address: swong1@tulane.edu.
245    10
$a Defining the Phenotype and Assessing Severity in Phosphoglucomutase-1 Deficiency / $c SY. Wong, LJ. Beamer, T. Gadomski, T. Honzik, M. Mohamed, SB. Wortmann, KS. Brocke Holmefjord, M. Mork, F. Bowling, J. Sykut-Cegielska, D. Koch, A. Ackermann, CA. Stanley, D. Rymen, A. Zeharia, M. Al-Sayed, T. Marquardt, J. Jaeken, D. Lefeber, DF. Conrad, T. Kozicz, E. Morava,
520    9_
$a OBJECTIVE: To define phenotypic groups and identify predictors of disease severity in patients with phosphoglucomutase-1 deficiency (PGM1-CDG). STUDY DESIGN: We evaluated 27 patients with PGM1-CDG who were divided into 3 phenotypic groups, and group assignment was validated by a scoring system, the Tulane PGM1-CDG Rating Scale (TPCRS). This scale evaluates measurable clinical features of PGM1-CDG. We examined the relationship between genotype, enzyme activity, and TPCRS score by using regression analysis. Associations between the most common clinical features and disease severity were evaluated by principal component analysis. RESULTS: We found a statistically significant stratification of the TPCRS scores among the phenotypic groups (P < .001). Regression analysis showed that there is no significant correlation between genotype, enzyme activity, and TPCRS score. Principal component analysis identified 5 variables that contributed to 54% variance in the cohort and are predictive of disease severity: congenital malformation, cardiac involvement, endocrine deficiency, myopathy, and growth. CONCLUSIONS: We established a scoring algorithm to reliably evaluate disease severity in patients with PGM1-CDG on the basis of their clinical history and presentation. We also identified 5 clinical features that are predictors of disease severity; 2 of these features can be evaluated by physical examination, without the need for specific diagnostic testing and thus allow for rapid assessment and initiation of therapy.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a algoritmy $7 D000465
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetické markery $7 D005819
650    _2
$a genotyp $7 D005838
650    _2
$a glykogenóza $x diagnóza $x enzymologie $x genetika $7 D006008
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $7 D009154
650    12
$a fenotyp $7 D010641
650    _2
$a fosfoglukomutasa $x nedostatek $x genetika $7 D010733
650    _2
$a fyzikální vyšetření $7 D010808
650    _2
$a analýza hlavních komponent $7 D025341
650    _2
$a regresní analýza $7 D012044
650    12
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Beamer, Lesa J $u Biochemistry and Chemistry Departments, University of Missouri, Columbia, MO.
700    1_
$a Gadomski, Therese $u Hayward Genetics Center, Tulane University School of Medicine, New Orleans, LA.
700    1_
$a Honzik, Tomas $u Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic.
700    1_
$a Mohamed, Miski $u Department of Pediatrics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
700    1_
$a Wortmann, Saskia B $u Salzburger Landeskliniken, Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria.
700    1_
$a Brocke Holmefjord, Katja S $u Department of Pediatric Habilitation, Stavanger University Hospital, Stavanger, Norway.
700    1_
$a Mork, Marit $u Department of Pediatric Habilitation, Stavanger University Hospital, Stavanger, Norway.
700    1_
$a Bowling, Francis $u Biochemical Diseases, Mater Children's Hospital, South Brisbane, Queensland, Australia.
700    1_
$a Sykut-Cegielska, Jolanta $u National Consultant in Paediatric Metabolic Medicine, Screening Department, The Institute of Mother and Child, Warsaw, Poland.
700    1_
$a Koch, Dieter $u Pediatric Cardiology, Bergisch Gladbacher Köln, Germany.
700    1_
$a Ackermann, Amanda $u Pediatric Endocrinology, The Children's Hospital of Philadelphia, Philadelphia, PA. $7 gn_A_00001011
700    1_
$a Stanley, Charles A $u Pediatric Endocrinology, The Children's Hospital of Philadelphia, Philadelphia, PA.
700    1_
$a Rymen, Daisy $u Department of Pediatrics, Universitair Ziekenhuis Leuven, Leuven, Belgium.
700    1_
$a Zeharia, Avraham $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.
700    1_
$a Al-Sayed, Moeen $u Department of Medical Genetics, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. $7 gn_A_00004831
700    1_
$a Marquardt, Thomas $u Department of Pediatrics, University of Münster, Münster, Germany.
700    1_
$a Jaeken, Jaak $u Centre for Metabolic Diseases, University Hospital Gasthuisberg, Herestraat, Leuven, Belgium.
700    1_
$a Lefeber, Dirk $u Department of Neurology, Radboudumc, Nijmegen, The Netherlands.
700    1_
$a Conrad, Donald F $u Department of Genetics, Washington University School of Medicine, Saint Louis, MO.
700    1_
$a Kozicz, Tamas $u Hayward Genetics Center, Tulane University School of Medicine, New Orleans, LA.
700    1_
$a Morava, Eva $u Hayward Genetics Center, Tulane University School of Medicine, New Orleans, LA; Department of Pediatrics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
773    0_
$w MED00002885 $t The Journal of pediatrics $x 1097-6833 $g Roč. 175, č. - (2016), s. 130-136.e8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27206562 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170830104701 $b ABA008
999    __
$a ok $b bmc $g 1239648 $s 984880
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 175 $c - $d 130-136.e8 $e 20160517 $i 1097-6833 $m The Journal of pediatrics $n J Pediatr $x MED00002885
GRA    __
$a NV16-31932A $p MZ0
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace